Blood Test Clues: Tell MS Apart from Similar Diseases

Credibility

Interest

Key Takeaway

Persistent high levels of a specific Epstein-Barr virus antibody (EBNA-1 IgG) can help tell multiple sclerosis (MS) apart from two similar diseases, MOGAD and NMOSD.

What They Found

Researchers looked at blood samples over time from people with MS, MOG antibody–associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD). They measured a kind of antibody tied to Epstein-Barr virus called EBNA-1 IgG and found that most people with MS kept high levels of this antibody in repeated tests. Very few people with MOGAD or NMOSD had these persistent high antibody levels, even when NMOSD patients tested negative for another common marker (AQP4). The result was confirmed in two separate groups of patients, which makes the finding stronger. In short, a steady high EBNA-1 IgG level over time appears common in MS but not in the other two conditions.

Who Should Care and Why

People with MS and their caregivers should care because this blood test could help doctors make a clearer diagnosis when symptoms or scans look similar to other diseases. Think of it like a fingerprint: if the EBNA-1 antibody level stays high over time, it points more toward MS than toward MOGAD or NMOSD. Neurologists and other health providers can use this information to choose the right treatments sooner, which matters because treatments differ between these diseases. Caregivers may find it comforting that a repeatable blood marker could reduce uncertainty, similar to getting several matching pieces of evidence before making an important decision. Patients who have unclear tests now (for example, those without the usual NMOSD marker) may particularly benefit from this additional blood test.

Important Considerations

This study looked back at stored samples (retrospective) rather than testing people going forward, which can introduce bias or missing information. High EBNA-1 IgG is linked to Epstein-Barr virus exposure, which most people have had, so the test works as a pattern over time rather than a single yes/no result. More studies in different settings and with diverse patient groups are still needed before this becomes a standard test everywhere.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Early Research MS Genetics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News